Randomized phase II study of oxaliplatin reintroduction and the biweekly XELOX in previously treated patients with metastatic colorectal cancer (ORION study)

ABSTRACT: Interventions: Oxaliplatin 130mg/m2 day1 Capacitabine 2000mg/m2 day1-14 every 3 weeks Oxaliplatin 85mg/m2 day1 Capacitabine 2000mg/m2 day1-7 every 2 weeks Primary outcome(s): time to treatment failure Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619574 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR